Abstract

Non-small cell lung carcinoma (NSCLC) is a malignant tumour with poor prognosis and high mortality. Platinum-based dual-agent chemotherapy is the main therapeutic regimen for this disease. In recent years, because of the introduction of molecular targeted therapy, various targeted therapeutic agents against epidermal growth factor receptor (EGFR) have been rapidly developed, which has become a research hotspot for NSCLC treatment. Here, we review the latest studies describing the features and types of EGFR pathogenic mutations, currently established EGFR-tyrosine kinase inhibitors from the first to fourth generation, including their action mechanisms, acquired resistance, and clinical applications, and potential challenges and perspectives that current researchers should address.

摘要

非小细胞肺癌（NSCLC）是一种预后差、死亡率高的恶性肿瘤。铂类双药化疗是该病的主要治疗方案。近年来，由于分子靶向治疗的引入，各种针对表皮生长因子受体（EGFR）的靶向治疗药物得到迅速发展，成为NSCLC治疗的研究热点。在这里，我们回顾了描述 EGFR 致病突变的特征和类型的最新研究，目前已建立的第一代至第四代 EGFR-酪氨酸激酶抑制剂，包括其作用机制、获得性耐药和临床应用，以及当前的潜在挑战和前景。研究人员应该解决。